Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lyle Fried

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Systems and Integrative Neuroscience|September 11, 2018
"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemicKenneth Blum, Edward J Modestino, Marjorie Gondré-Lewis, et al.
Journal of Systems and Integrative Neuroscience|December 12, 2019
Death by Opioids: Are there non-addictive scientific solutions?B William Downs, Kenneth Blum, David Baron, et al.
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Current Pharmaceutical Biotechnology|December 11, 2019
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family AffairLyle Fried, Edward J Modestino, David Siwicki, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Systems and Integrative Neuroscience|September 11, 2018
"Dopamine homeostasis" requires balanced polypharmacy: Issue with destructive, powerful dopamine agents to combat America's drug epidemicKenneth Blum, Edward J Modestino, Marjorie Gondré-Lewis, et al.
Journal of Systems and Integrative Neuroscience|December 12, 2019
Death by Opioids: Are there non-addictive scientific solutions?B William Downs, Kenneth Blum, David Baron, et al.
Current Psychopharmacology|May 21, 2020
In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk TestingKenneth Blum, David Baron, Lisa Lott, et al.
Current Pharmaceutical Biotechnology|December 11, 2019
Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family AffairLyle Fried, Edward J Modestino, David Siwicki, et al.
Frontiers in Bioscience (Elite Edition)|September 21, 2017
Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependenceKenneth Blum, Amanda L C Chen, Panayotis K Thanos, et al.
International Journal of Genomics and Data Mining|September 11, 2018
The Benefits of Genetic Addiction Risk Score (GARSKenneth Blum, Edward J Modestino, Marjorie Gondre-Lewis, et al.
Pageof 2